Fortunately, imatinib, a tyrosine kinase inhibitor (TKI) also known as a BCR–ABL inhibitor, revolutionizes CML treatment as a groundbreaking targeted drug (16). The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.